 NEW YORK, Sept. 13, 2022 GLOBE NEWSWIRE -- IN8bio, Inc. Nasdaq: INAB, a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced William Ho, IN8bios Chief Executive Officer will be participating in a fireside chat at 10:30 a.m. ET tomorrow, Wednesday, September 14, at the H.C. Wainwright Co. 24th Annual Global Investment Conference. 